Rhodes claims that in his research, the kit has had 85 percent accuracy in
identifying patients with lung cancer.
Not exact matches
Research from McMaster University has
identified new regulators of brain metastases in
patients with lung cancer.
The difference
with Xalkori is that a test exists to
identify that slim percentage of
lung cancer patients (about 8,000 people in the United States and 40,000 worldwide each year) who would respond well.
With the blood test, it is possible, at a very early stage of
cancer (colon
cancer, gastric
cancer,
lung cancer) to
identify patients who are at high risk of developing life - threatening metastases.
Lung cancer treatment is an evolving field of science, currently there are several pathways under investigation as a possible treatment target.1 - 3 Targeted treatment is currently considered to be more efficient compared to the non-specific cytotoxic drugs, however; the small number of
patients identified with mutations, limit the application of these drugs.